Has the rare disease voice been lost in translation?
Interesting piece on the challenges facing those trying to gain approval for new treatments for rare diseases. In rare diseases more than...
Contributors
-
Account Manager -
Associate Consultant -
President, USA -
-
Publications Executive -
Project Director -
Associate Consultant -
Consultant -
Consultant -
Senior Consultant -
SVP -
Master Practitioner: Patient Insights -
Publications Assistant -
EVP, Oncology Practice Head -
Senior Strategy Consultant -
Chief Commercial Officer -
US CEO -
Account Manager -
Senior Consultant -
Associate Editorial Director -
Sr. Research Analyst -
Associate Consultant -
Principal -
Research Executive -
Account Director -
Consultant -
Vice President -
Head of MedErgy (CH-MedErgy) -
Marketing and Communications Manager -
Project Manager -
Project Manager -
Managing Consultant -
Senior Consultant -
Project Director -
Executive Vice President, Strategic Collaborations -
Associate Consultant
Cello Health Archive
- December 2019 (2)
- November 2019 (4)
- October 2019 (1)
- September 2019 (2)
- August 2019 (4)
- July 2019 (4)
- June 2019 (4)
- May 2019 (12)
- April 2019 (11)
- March 2019 (5)
- February 2019 (12)
- January 2019 (1)
- October 2018 (2)
- August 2018 (5)
- July 2018 (7)
- June 2018 (5)
- May 2018 (5)
- April 2018 (6)
- March 2018 (9)
- February 2018 (11)
- January 2018 (4)
- December 2017 (8)
- November 2017 (21)
- October 2017 (35)
- September 2017 (18)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (1)
- February 2017 (2)
- January 2017 (1)
- December 2016 (1)
- October 2016 (1)
Is it becoming possible to turn back time?
Perhaps at the cellular level, for now. Researchers based in the UK recently discovered a way to switch on cell splicing factors –...
What is the role of AI in medicine? How the vast amount of data is driving a shift toward AI
In 2012, IBM estimated that 2.5 exabytes (i.e., 2.5 billion gigabytes) of data was generated every day. What that figure is today has...
Medication adherence - a step too far?
My granddad used to have one of those a biscuit tins, the ones most of us recognise as a sewing box. After every meal my siblings or I...
1st Digital Medicine Approved!
Abilify MyCite, a combination of Otsuka's Abilify and Proteus Digital Health's ingestible sensor, provides the ability to track the...
Scared straight? Stimulating disease symptoms to prompt prevention
Here’s a fascinating piece about a new approach to helping non-sufferers really KNOW what it’s like to experience the symptoms of a...
Now that the digital technology toothpaste is coming out of the tube...
In this March 2017 article in Forbes magazine, contributor Daniel Newman speculates that increasing integration of digital technology...
CRISPR: a tool for genome editing
The genome editing technology ‘Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR, pronounced ‘crisper’)’, was in the news...
Are we approaching a post-antibiotics era?
Antibiotic resistance is the ability of microbes to survive antibiotic treatment. It is an inevitable consequence of the “Red Queen”...
Virtual GP appointments - timely advance or doomed to fail?
Whilst GP surgeries were one of the first sectors to fully implement the use of computers to log personal information, calls to open...
How one of the oldest and cheapest medicines has helped researchers kill cancer cells in less than three days
Digoxin (digitalis, a purified product of the foxglove plant) has been around for nearly a century and is ‘cheap as chips’. It is...
1/3 fewer new rare disease treatments developed in future?
The Orphan Drug Tax Credit has assisted in the creation of an increased number of orphan drug treatments since its inception in 1983 but...
How can your gut make or break your cancer treatment?
Continuing the dive into the impact of the human microbiome on the development of non-gastro-intestinal diseases and to follow up on last...
Lab-Grown Blood Vessels on the Horizon?
Artificial grafts, which are commonly used in kidney dialysis patients, currently lead to approximately 50% of patients experiencing...
Immune privilege vs immunotherapy – an impenetrable barrier?
Immuno-oncology has frequently been hailed as the ‘new frontier’ in oncological medicine, with many millions being invested by...
The scoop is in the poop
The implications of microbiome in cancer treatment first came to my attention at a plenary talk by Jennifer Wargo at the NCRI conference...
Could a lack of diversity in our microbiome have implications for Alzheimer's Disease?
Though a person's microbiome is generally stable throughout his/her lifetime, there are notable differences from person to person. Though...
Retrotope provide the first treatment for INAD patients, and even more besides
Retrotope is a clinical-stage company, within the area of degenerative disease. Their first first lead candidate, RT001, today became an...
Treg cells: peacekeepers of the immune system or stealthy saboteurs? It’s big business either way.
Regulatory T cells (Tregs; pronounced 'tee-regs'), are a critical negotiator in the body’s immune response. ‘Killer’ and ‘helper’ T...
Education through earned media, the key to innovation’s success?
Earned media and public campaigns have traditionally been left to patient support groups looking to raise money and awareness for...
Am I increasing my risk of Stomach Cancer?
I recently wrote a short piece on whether I should continue taking PPIs (proton pump inhibitors) as the growing evidence base seems to...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net